BioCryst Pharmaceuticals, Inc.

DB:BO1 Stock Report

Market Cap: €1.7b

BioCryst Pharmaceuticals Valuation

Is BO1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BO1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€52.39
Fair Value
84.1% undervalued intrinsic discount
11
Number of Analysts

Below Fair Value: BO1 (€8.32) is trading below our estimate of fair value (€52.39)

Significantly Below Fair Value: BO1 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BO1?

Key metric: As BO1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BO1. This is calculated by dividing BO1's market cap by their current revenue.
What is BO1's PS Ratio?
PS Ratio4.5x
SalesUS$412.58m
Market CapUS$1.79b

Price to Sales Ratio vs Peers

How does BO1's PS Ratio compare to its peers?

The above table shows the PS ratio for BO1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.7x
BIO3 Biotest
1.6x3.6%€1.4b
FYB Formycon
15.1x24.6%€919.9m
HPHA Heidelberg Pharma
13.2x16.6%€111.9m
2INV 2invest
8.8xn/a€68.4m
BO1 BioCryst Pharmaceuticals
4.5x14.0%€1.8b

Price-To-Sales vs Peers: BO1 is good value based on its Price-To-Sales Ratio (4.5x) compared to the peer average (9.7x).

Price to Sales Ratio vs Industry

How does BO1's PS Ratio compare vs other companies in the DE Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
BO1 4.5xIndustry Avg. 8.5xNo. of Companies5PS0612182430+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BO1 is good value based on its Price-To-Sales Ratio (4.5x) compared to the European Biotechs industry average (8.5x).

Price to Sales Ratio vs Fair Ratio

What is BO1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BO1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.5x
Fair PS Ratio2.7x

Price-To-Sales vs Fair Ratio: BO1 is expensive based on its Price-To-Sales Ratio (4.5x) compared to the estimated Fair Price-To-Sales Ratio (2.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BO1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€8.32
€14.71
+76.7%
42.4%€28.89€7.70n/a11
Feb ’26€7.54
€14.95
+98.2%
42.4%€29.36€7.83n/a11
Jan ’26€7.32
€14.00
+91.4%
43.2%€28.35€7.56n/a11
Dec ’25€7.05
€13.46
+90.9%
43.3%€27.58€7.36n/a11
Nov ’25€7.39
€13.08
+77.0%
44.0%€27.16€6.34n/a11
Oct ’25€6.77
€13.19
+94.9%
44.0%€27.38€6.39n/a11
Sep ’25€7.79
€13.19
+69.3%
44.0%€27.38€6.39n/a11
Aug ’25€6.68
€12.89
+92.8%
46.7%€27.61€5.52n/a11
Jul ’25€6.15
€13.00
+111.3%
46.7%€27.86€5.57n/a11
Jun ’25€6.02
€13.00
+116.0%
46.7%€27.86€5.57n/a11
May ’25€3.87
€12.71
+228.3%
46.7%€27.60€5.52n/a11
Apr ’25€4.84
€12.71
+162.5%
46.7%€27.60€5.52n/a11
Mar ’25€5.17
€12.70
+145.8%
46.7%€27.57€5.51n/a11
Feb ’25€4.87
€12.70
+160.8%
46.7%€27.57€5.51€7.5411
Jan ’25€5.57
€12.88
+131.3%
46.2%€27.41€5.48€7.3211
Dec ’24€5.35
€12.88
+140.9%
46.2%€27.41€5.48€7.0511
Nov ’24€5.37
€14.32
+166.7%
46.2%€28.26€7.54€7.3910
Oct ’24€6.81
€14.23
+109.0%
46.2%€28.08€7.49€6.7710
Sep ’24€6.52
€13.72
+110.4%
47.1%€27.26€7.27€7.7910
Aug ’24€6.67
€13.73
+105.8%
48.1%€27.36€7.30€6.6810
Jul ’24€6.43
€13.99
+117.7%
47.2%€27.71€7.39€6.1510
Jun ’24€7.62
€13.57
+78.1%
45.8%€27.22€7.26€6.0211
May ’24€6.82
€13.50
+97.9%
45.5%€27.17€7.24€3.8711
Apr ’24€7.41
€14.58
+96.9%
41.7%€28.30€7.55€4.8411
Mar ’24€8.23
€14.58
+77.3%
41.7%€28.30€7.55€5.1711
Feb ’24€9.38
€15.87
+69.3%
36.2%€28.51€9.50€4.8710
Analyst Price Target
Consensus Narrative from 11 Analysts
€14.14
Fair Value
41.1% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/11 00:33
End of Day Share Price 2025/02/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioCryst Pharmaceuticals, Inc. is covered by 30 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Tazeen AhmadBofA Global Research
Dae Gon HaBTIG